Scientists showed that a bacterial infection and bacterial toxins could trigger an immune response that led to the production of dietary-antigen-specific IgE antibodies in mice, which were limited to the intestine.
Aguilera-Lizarraga, J., Florens, M. V., Viola, M. F., Jain, P., Decraecker, L., Appeltans, I., Cuende-Estevez, M., Fabre, N., Van Beek, K., Perna, E., Balemans, D., Stakenborg, N., Theofanous, S., Bosmans, G., Mondelaers, S. U., Matteoli, G., Ibiza Martínez, S., Lopez-Lopez, C., Jaramillo-Polanco, J., … Boeckxstaens, G. E. (2021). Local immune response to food antigens drives meal-induced abdominal pain. Nature, 1–6. https://doi.org/10.1038/s41586-020-03118-2Cite
The regulatory acceptance enables a team of gastroenterologists at Beth Israel Deaconess Medical Center to initiate a Phase II randomized, triple-blind, and placebo-controlled clinical trial to investigate the role of the gut microbiome in patients with Irritable Bowel Syndrome, as well as the impact of DS-01™ on both intestinal cells and metabolic output of the native intestinal microbial communities.
Immunic, Inc.announced dosing of the first healthy volunteer in the company’s phase I clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function.
The authors provide an update on the literature to understand how genetics, diet, and the gut microbiota influence the crosstalk between immune and non-immune cells resulting in inflammation observed in multiple colonic pathologies.